Vanguard Personalized Indexing Management LLC Sells 236 Shares of DaVita Inc. (NYSE:DVA)

Vanguard Personalized Indexing Management LLC lessened its stake in DaVita Inc. (NYSE:DVA) by 6.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,518 shares of the company’s stock after selling 236 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in DaVita were worth $368,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Hanseatic Management Services Inc. bought a new stake in DaVita in the third quarter valued at approximately $36,000. Principal Securities Inc. bought a new stake in shares of DaVita in the 4th quarter valued at $37,000. GAMMA Investing LLC acquired a new stake in shares of DaVita during the fourth quarter worth $60,000. Tacita Capital Inc bought a new position in DaVita during the third quarter worth $118,000. Finally, Federated Hermes Inc. lifted its holdings in DaVita by 1,284.4% in the third quarter. Federated Hermes Inc. now owns 1,246 shares of the company’s stock valued at $118,000 after buying an additional 1,156 shares during the period. Institutional investors and hedge funds own 90.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. StockNews.com lowered DaVita from a “strong-buy” rating to a “buy” rating in a research report on Monday, May 6th. TheStreet upgraded DaVita from a “c+” rating to a “b-” rating in a report on Wednesday, February 7th. UBS Group lifted their price objective on shares of DaVita from $113.00 to $134.00 and gave the company a “buy” rating in a research note on Wednesday, February 14th. Truist Financial increased their target price on shares of DaVita from $135.00 to $150.00 and gave the stock a “hold” rating in a research note on Wednesday, May 15th. Finally, Barclays raised their price target on shares of DaVita from $133.00 to $150.00 and gave the stock an “equal weight” rating in a report on Monday, May 6th. Two analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $144.67.

DaVita Price Performance

Shares of NYSE:DVA opened at $138.54 on Monday. The stock’s 50 day moving average is $135.26 and its 200-day moving average is $119.24. DaVita Inc. has a twelve month low of $71.51 and a twelve month high of $145.04. The company has a quick ratio of 1.37, a current ratio of 1.43 and a debt-to-equity ratio of 7.95. The firm has a market capitalization of $12.15 billion, a price-to-earnings ratio of 15.74, a PEG ratio of 1.06 and a beta of 1.04.

DaVita (NYSE:DVA) last released its quarterly earnings data on Thursday, May 2nd. The company reported $2.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.95 by $0.43. The firm had revenue of $3.07 billion for the quarter, compared to analyst estimates of $3.03 billion. DaVita had a net margin of 6.61% and a return on equity of 68.52%. The business’s quarterly revenue was up 6.9% compared to the same quarter last year. During the same period last year, the firm earned $1.58 earnings per share. Sell-side analysts forecast that DaVita Inc. will post 9.62 EPS for the current fiscal year.

Insider Buying and Selling at DaVita

In other news, Director Barbara J. Desoer sold 5,030 shares of the firm’s stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $138.81, for a total value of $698,214.30. Following the transaction, the director now owns 10,954 shares in the company, valued at $1,520,524.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 2.00% of the company’s stock.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.